Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Pyxis Oncology Inc (PYXS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: PYXS (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6
1 Year Target Price $6
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 182.32% | Avg. Invested days 20 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 115.35M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 7 | Beta 1.15 | 52 Weeks Range 0.83 - 5.39 | Updated Date 09/12/2025 |
52 Weeks Range 0.83 - 5.39 | Updated Date 09/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.59 |
Earnings Date
Report Date 2025-08-14 | When - | Estimate -0.34 | Actual -0.3 |
Profitability
Profit Margin - | Operating Margin (TTM) -676.1% |
Management Effectiveness
Return on Assets (TTM) -31.25% | Return on Equity (TTM) -74.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 45871731 | Price to Sales(TTM) 40.91 |
Enterprise Value 45871731 | Price to Sales(TTM) 40.91 | ||
Enterprise Value to Revenue 16.27 | Enterprise Value to EBITDA 1.09 | Shares Outstanding 62018100 | Shares Floating 41180042 |
Shares Outstanding 62018100 | Shares Floating 41180042 | ||
Percent Insiders 23.39 | Percent Institutions 33.73 |
Upturn AI SWOT
Pyxis Oncology Inc
Company Overview
History and Background
Pyxis Oncology, Inc. is a clinical-stage oncology company focused on developing next-generation therapies to target difficult-to-treat cancers. Founded in 2019, the company leverages its Antibody-Drug Conjugate (ADC) and immunotherapy expertise to advance novel treatments.
Core Business Areas
- Antibody-Drug Conjugates (ADCs): Developing ADCs targeting specific tumor antigens to deliver cytotoxic payloads directly to cancer cells.
- Immunotherapies: Developing immunotherapies designed to enhance the body's immune response against cancer.
Leadership and Structure
Lara S. Sullivan, M.D. is the Chief Executive Officer. The company has a structured R&D team focusing on preclinical development and clinical trials.
Top Products and Market Share
Key Offerings
- PYX-201: An anti-EDB-ADC targeting solid tumors. Currently in Phase 1 clinical trials. Competitors include companies developing similar ADC therapies and anti-cancer treatments for the same indications.
- PYX-106: An anti-Siglec-15 antibody designed to enhance immune response against tumors. Currently in preclinical development. Competitors include companies developing similar immunotherapy approaches.
Market Dynamics
Industry Overview
The oncology market is a rapidly growing and competitive sector driven by the increasing prevalence of cancer and advancements in treatment technologies. Targeted therapies and immunotherapies are key growth areas.
Positioning
Pyxis Oncology aims to differentiate itself through its expertise in ADC and immunotherapy development. Its competitive advantage lies in targeting novel tumor antigens and developing innovative combination therapies.
Total Addressable Market (TAM)
The global oncology market is expected to reach over $300 billion by 2025. Pyxis Oncology is positioned to capture a portion of this TAM through successful development and commercialization of its pipeline candidates.
Upturn SWOT Analysis
Strengths
- Novel ADC and immunotherapy pipeline
- Experienced leadership team
- Strong scientific expertise
Weaknesses
- Limited clinical data
- High reliance on clinical trial success
- Competition from established pharmaceutical companies
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline into new indications
- Advancements in targeted therapy technologies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from new and existing therapies
- Economic downturn impacting investment in biotech
Competitors and Market Share
Key Competitors
- ImmunoGen, Inc. (IMGN)
- Seagen Inc. (SGEN)
- ADC Therapeutics SA (ADCT)
Competitive Landscape
Pyxis Oncology competes in a crowded market but aims to differentiate itself through novel targets and combination therapies. Its advantage lies in its focused expertise but faces challenges from larger, more established competitors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical development and initiation of clinical trials.
Future Projections: Future growth is dependent on positive clinical trial outcomes and potential partnerships.
Recent Initiatives: Recent initiatives include advancing clinical trials for PYX-201 and continuing preclinical development of PYX-106.
Summary
Pyxis Oncology is a clinical-stage company with potential in the ADC and immunotherapy space, particularly with its PYX-201 program. The company is reliant on positive clinical trial results to increase stock value. Pyxis is a long way from gaining market share when compared to some of the bigger competitors. A key factor for Pyxis will be to look at strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Pyxis Oncology Investor Relations
- SEC Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share data is estimated and may vary. Clinical trial outcomes are uncertain and can impact financial performance.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pyxis Oncology Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2021-10-08 | CEO, President, Chief Medical Officer & Director Dr. Lara S. Sullivan M.D., MBA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 44 | Website https://www.pyxisoncology.com |
Full time employees 44 | Website https://www.pyxisoncology.com | ||
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.